AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06358937 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Root Planing using ultrasonic and curettes
Description: Scaling and root planing (SRP) using ultrasonic device at a moderate setting and with the appropriate tips and curettes will be also used where indicated and time spent in SRP on each tooth will not be restricted.
Study NCT05116540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-adMSCs
Description: Autologous product
Study NCT05116540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study NCT05603039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: 5 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
Study NCT05603039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1604
Description: 200mg#D1#Q3W IV
Study NCT05603039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV
Study NCT04385355 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional transmucosal abutment design
Description: The macroscopic design of the intermediate transmucosal abutment will be evaluated on terms of the marginal peri-implant bone levels using two identical devices, if only being the test device narrower than the control one
Study NCT04385355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrow transmucosal abutment design
Description: The macroscopic design of the intermediate transmucosal abutment will be evaluated on terms of the marginal peri-implant bone levels using two identical devices, if only being the test device narrower than the control one
Study NCT06178978 — intervention group
Intervention type: DEVICE
Intervention: KalEYEdoscope
Description: KalEYEdoscope is a digital, handheld device utilizing shape-discrimination hyperacuity to distinguish the severity of age-related macular degeneration. In the future, developing such a device for home monitoring of macular degeneration may increase access to timely treatment to prevent vision loss.~This study was conducted at the Kellogg Eye Center in Ann Arbor. Participants in the outpatient setting who agreed to enroll in the study tested the device and provided user feedback via a questionnaire as well as completed questionnaires about their visual function. This study assessed the usability, comfort, duration, ergonomics, and ease of use of the device among AMD patients in a single session.
Study NCT04863794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7248824
Description: A single dose of 10 mg RO7248824 will be used for this PET study in healthy participants.
Study NCT04836533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Computerized Cognitive Training
Description: Participants will complete 4 weeks of executive functioning / processing speed training through the BrainHQ platform on their personal computers.
Study NCT04836533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Open-label antidepressant treatment
Description: Participants will be assigned to open-label or placebo-controlled antidepressant treatment for 8 weeks.
Study NCT04836533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Solitaire Training
Description: Participants will complete 4 weeks of Solitaire training through the BrainHQ platform on their personal computers.
Study NCT04836533 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo-controlled antidepressant treatment
Description: Participants will be told they have a 50/50 chance of receiving a placebo or antidepressant.
Study NCT05375188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: DOSAGE FORM: IV Infusion DOSAGE: 0.4 mcg/kg/hr
Study NCT05375188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: DOSAGE FORM: IV Infusion DOSAGE: Equal Volume
Study NCT04957225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIRAA (Multimodal Intensive Rehabilitation of Aphasia and Apraxia of speech)
Description: Multimodal intensive treatment of aphasia and AOS
Study NCT05706168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treadmill exercise
Description: Treadmill exercise is a form of aerobic exercise training that involves the use of a treadmill machine in a structured exercise programs.
Study NCT05706168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycle ergometer exercise
Description: Cycle ergometer exercise is a form of aerobic exercise training that involves the use of a stationery recumbent bike in a structured exercise programs.
Study NCT06549582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taohong Tongluo Xiaoban Prescription
Description: Chinese herbal medicine Taohong Tongluo Xiaoban prescription, which includes Pinelliae Rhizoma, Poria, Bambusae caulis in taenias, Aurantii Fructus Immaturus, Arisaema cum bile, Acori Tatarinowii Rhizoma, Persicae Semen, Carthami Flos, Chuanxiong Rhizoma and Paeoniae Radix Rubra as a once - daily dosage with one administration per dose
Study NCT06549582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fundamental medical treatment
Description: The specific methods were developed in accordance with the 2010 Chinese Guidelines for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack. It primarily involves managing risk factors such as hypertension, diabetes, abnormal lipid metabolism, etc., and implementing antithrombotic therapy including antiplatelet agents (aspirin, clopidogrel, dipyridamole, dipyridamole + aspirin, clopidogrel + aspirin, silostazole, triflurosal, etc). For the management of post-stroke mood disorders, cognitive impairments, and spastic paralysis, pharmacological interventions encompass oral administration of anxiolytic or antidepressant agents, anti-dementia medications, as well as muscle relaxants.
Study NCT06549582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fundamental medical treatment
Description: The specific methods were developed in accordance with the 2010 Chinese Guidelines for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack. It primarily involves managing risk factors such as hypertension, diabetes, abnormal lipid metabolism, etc., and implementing antithrombotic therapy including antiplatelet agents (aspirin, clopidogrel, dipyridamole, dipyridamole + aspirin, clopidogrel + aspirin, silostazole, triflurosal, etc). For the management of post-stroke mood disorders, cognitive impairments, and spastic paralysis, pharmacological interventions encompass oral administration of anxiolytic or antidepressant agents, anti-dementia medications, as well as muscle relaxants.
Study NCT05214924 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injectable platelet-rich fibrin
Description: Intra-articular injection of injectable platelet-rich fibrin into temporomandibular joint/joints with diagnosed mild to moderate degenerative joint disease.
Study NCT05214924 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich plasma
Description: Intra-articular injection of platelet-rich plasma into temporomandibular joint/joints with diagnosed mild to moderate degenerative joint disease.
Study NCT05346601 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chiauranib
Description: 50mg po only once
Study NCT04813016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramal 1
Description: Early intraperitoneal injection of tramal and bupivacaine
Study NCT05512624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach
Description: For treatment group participants, they will then have weekly meetings with a counselor lasting no more than 1.5 hours per session, and a total of approximately 10 sessions. Both treatment and wait list participants will then complete the assessment instrument at 3 months and 6 months post-enrollment (each lasting no more than 1.5 hours). All total, it is expected that treatment group participants will have up to 13 meetings with a study team member or counselor over the course of their participation.~Wait list group participants will have 3 meetings with a study team member over the course of their participation. If the treatment is deemed to be effective these wait list participants will be the first adults to be offered the intervention after trial completion.
Study NCT05618899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIGH INTENSITY INTERVAL TRAINING
Description: Training should be done on treadmill for 25-30 minutes.. Training proceed for 1 month once a day
Study NCT04927221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC371739 Tablets
Description: Participants received one of 5 dose levels of DC371739 administered as single oral doses.
Study NCT04927221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally administered as comparison
Study NCT05618899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MODERATE INTENSITY EXERCISE
Description: moderate intensity exercises consist of generally 30-60 minutes of aerobic exercises at 64-76% of peak heart rate. Training should be done on treadmill for 30-60 minutes. Training proceed for 1 month once a day
Study NCT04582591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol 100 MG/ML
Description: Patients receive cannabidiol before and after treatment with chemotherapy
Study NCT04744584 — intervention group
Intervention type: OTHER
Intervention: Medication reconciliation
Description: MR will be performed directly upon entering the patient's hospital for a first PAH or HTP-Thrombo embolic assessment, just after inclusion. Information regarding the treatments taken by the patient at the time of admission will be retrieved. The entry medication assessment will then be compared with the first medical prescription in order to identify whether medications have been forgotten, prescribed at a different dosage or prescribed when not indicated, etc. All of these differences will be considered medication errors if the reason for the discrepancy is not entered in the patient medical file.
Study NCT04744584 — intervention group
Intervention type: OTHER
Intervention: Medication reconciliation
Description: After inclusion of the patient, the MR will be carried out retrospectively, that is to say that the information concerning the treatments taken by the patient at the time of the first assessment will be retrieved during the period of the first reassessment (therefore with a delay of 12 months depending on the deadline for the first assessment). All these discrepancies will be considered medication errors if the reason for the discrepancy was not entered in the patient's computerized medical record (IMR).
Study NCT05612230 — intervention group
Intervention type: OTHER
Intervention: Data analysis
Description: Data analysis is based on a single database from the National Health Medical Data (North Center).
Study NCT03754322 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LAMP
Description: LAMP testing involves taking a blood specimen using venous puncture, extracting DNA and performing a commercial CE-marked LAMP malaria assay to obtain a malaria result (presence/absence of parasite DNA) at the species level
Study NCT03754322 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microscopy/RDT
Description: Standard of care management of malaria in pregnancy relies on microscopy and/or RDT for diagnosis
Study NCT06555614 — intervention group
Intervention type: OTHER
Intervention: Acellular Dermal Matrix(ADM)
Description: A comparison of the short-term complications associated with acellular dermal matrix in the test group and the control group.
Study NCT05291949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATLASense RAPHAEL PolyMonitor
Description: All patients will be monitored using the ATLASense RAPHAEL PolyMonitor during their surgery.
Study NCT03754322 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Microscopy/RDT
Description: Standard of care management of malaria in pregnancy relies on microscopy and/or RDT for diagnosis
Study NCT05582785 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hyperfine MRI
Description: Patients who have a standard of care MRI, CT or US will undergo a low-field MRI utilizing Hyperfine either at the patient's bedside or in the department of Radiology. Results of the Hyperfine MRI will not be used for clinical care and will only be available to members of the research team for review.
Study NCT06241755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG for Therapeutic Use
Description: Specification: 60 mg (6.0×10\^7 CFU)/vial, each vial contains BCG 60 mg and each mg BCG shall have a count of live bacteria not less than 1.0×10\^6 CFU.~Usage \& dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h.
Study NCT06241755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG for Therapeutic Use
Description: Specification: 60 mg/vial with a count of live BCG bacteria not less than 1.0×10\^6 CFU/mg.~Usage \& dosage: Dissolving two vials (120 mg) into 40-50 mL normal saline and shaking thoroughly. Following the procedures of surgical cauterization, inserting a Foley tube into cystic cavity and instilling diluted drug solution. After instillation, constantly changing body positions of a patient, such as left/right recumbent and supine/prostrate. Each position is maintained for around 30 min. Self-discharging drug solution after 2h.
Study NCT05879679 — intervention group
Intervention type: BEHAVIORAL
Intervention: Food craving induction
Description: Standardized craving induction procedure will be used, based on exposure to food-related images (https://www.lippc2s.fr/food-cal-pictures/). Craving intensity will be measured by visual analogic scale before and after the induction sequence.
Study NCT06216470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 is a human monoclonal antibody that binds the antigenic loop present in all forms of the surface envelope protein (small, middle, and large HBsAg).
Study NCT04813016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramal 2
Description: Late intraperitoneal injection of tramal and bupivacaine
Study NCT05345977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eMotiph
Description: Mobile application for patients with schizophrenia.
Study NCT04764279 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OPTIFAST dietary supplement
Description: Participants will use Optifast Nutrition Supplement as previously described
Study NCT06161870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: individualized vancomycin dosing based on the population pharmacokinetics (PK) model
Description: The experimental group will be guided at the bedside with individualized vancomycin dosing by a drug dosimetry software tool that incorporates a PK model developed by Roberts JA et al. for data from sepsis patients. The model developed by Roberts JA et al. has been validated in multiple centers to have a good ability to predict the concentration-time data of patients. Once the basic information of participants such as gender, age, body weight, and creatinine clearance rate (CCR) is entered, the software tool can calculate the dosing regimen that is estimated to achieve the pharmacodynamic (PD) target. The area under the curve (AUC24) of 400-600mg·h/L is identified as the PD target of vancomycin.
Study NCT06161870 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: empirical vancomycin dosing
Description: The control group will be administered empirically (15-20 mg/kg vancomycin infused intermittently every 8-12 hours depending on the actual body weight of participants).
Study NCT04997083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maxillary Expander with Differential Opening (EDO)
Description: The EDO is designed with two expansion screws positioned transversely. When more expansion is required between the canines, the anterior screw can be further activated. Both expansion screws can be activated to open in a parallel configuration. Pivoting corner screws allow for different amounts of expansion without significant risk of binding during activation.
Study NCT04997083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Petit face mask
Description: The face mask is anatomical, multi-adjustable, lightweight and an ideal therapeutic alternative for the correction of Class III malocclusion. It consists of forehead cap, chin cap, and cross bar.
Study NCT04813016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 1
Description: Early intraperitoneal injection of dexmedetomidine and bupivacaine
Study NCT04813016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine 2
Description: Late intraperitoneal injection of dexmedetomedine and bupivacaine
Study NCT06257316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPHEDrine Hydrochloride 5 mg/ml
Description: In the present study, the expected rate of recovery of the internal carotid artery according to the dose of the inotropic agent was similar to that in a previous study in which the fraction maintaining mean arterial pressure within 80% of baseline by dose of inotropic agent was 0.9% for the ephedrine 0.1, 0.6, 0.8, 1. 0, 1.2, and 1.4 doses (mg/kg) were 9.9%, 21%, 41%, 47%, 65.5%, and 40%, respectively (Br J Anaesth. 2023 May;130(5):603-610), and it was assumed that the rate of internal carotid artery recovery by inotrope dose would be 90% of that result.~The study will randomize to dose in six cohorts and will include dose group and cohort variables in a logistic regression model to assess the trend between inotropic dose and rate of carotid revascularization after correcting for cohort effects on the outcome variable.
Study NCT04882943 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Description: Quality of life questionnaires
Study NCT05181228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based Education Based on Family-Centered Empowerment Model
Description: Parents in the intervention group will receive care for ten weeks using the family-centered empowerment model (FCEM). The first step (two weeks) is to increase knowledge. For this purpose, they will receive web-based training on cancer. The second step (four weeks) is to develop parents' self-efficacy and problem-solving skills. A web-based training and group meeting will be held to share information and experiences on the evaluation and control of the side effects of the treatment and to increase their self-efficacy in care. The third step (three week) was to increase self-esteem through participation in the training. At this stage, each participant will be asked to teach one of the family members responsible for the child's care what they have learned in the last two sessions. In the fourth step (one week), all participants in the intervention group will be evaluated by asking questions about the topics discussed in the second and third sessions and the overall content taught.
Study NCT05165082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% ophthalmic solution
Description: Apply on affected finger or toes twice daily for 8 weeks
Study NCT05165082 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cryotherapy with liquid nitrogen
Description: Conducted on affected finger or toes every other week for four sessions.
Study NCT05165082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy with liquid nitrogen
Description: Conducted on affected finger or toes every other week for four sessions.
Study NCT04949035 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of mental state and quality of life
Description: Patients qualified for rehabilitation will be assessed for stress levels as well as symptoms of anxiety and depression and quality of life before rehabilitation began
Study NCT05031390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led training
Description: Patients will undergo a 12-week physiotherapist-led training program consisting of 8 supervised sessions and home-based training in between
Study NCT05568264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy intervention
Description: The intervention is based on five principles: active learning, caregiver engagement, environmental enrichment, strengths-based approach, and dose. The intervention will start in the NICU and continue until 12-months corrected age. Infants in the intervention group will receive up to two therapist visits per week in addition to standard of care physical therapy. Caregivers will be asked to work with their infant on activities provided by the therapist. The therapist will provide resources to support the caregiver in working on these activities with their child, and caregivers will be asked to complete the activities for as much time as possible, throughout the day. Therapists will work with caregivers to identify ways to incorporate activities into their day. Caregiver engagement and caregiver ability to complete sessions and activity recommendations will be monitored.
Study NCT04906161 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D and calcium levels
Description: Mini VIDAS® compact multiparametric immunoanalyzer for vitamin D analysis (BIOMERIEUX- France)
Study NCT05325853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-920
Description: AG-920 Sterile Topical Ophthalmic Solution
Study NCT05325853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proparacaine Ophthalmic
Description: 0.5% Proparacaine Hydrochloride
Study NCT05786898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEAR-TSA
Description: Neuropsychological and Educational Approach of Cognitive Remediation adapted to autism~32 sessions spread over 4 to 8 months (1 session per week for minors, 2 sessions per week for adults), lasting 90 to 120 minutes